GeneHealth - Your precision medicine

Dilated Cardiomyopathy 1a

Disease Details

Family Health Simplified

Buy Membership

Description: Dilated cardiomyopathy 1A is a genetic disorder characterized by the enlargement and weakening of the heart's left ventricle, leading to impaired pumping efficiency and often heart failure. One-sentence description: Dilated cardiomyopathy 1A is a hereditary condition where the heart's main pumping chamber enlarges and weakens, causing reduced cardiac function and potential heart failure.
Type: Dilated cardiomyopathy 1A (DCM1A) is an autosomal dominant genetic disorder.
Signs And Symptoms: Signs and symptoms of dilated cardiomyopathy include:

- Shortness of breath, especially during exertion or when lying down
- Fatigue
- Swelling in the legs, ankles, and feet (edema)
- Irregular heartbeats (arrhythmias)
- Dizziness or lightheadedness
- Chest pain or discomfort
- Weight gain due to fluid retention
- Persistent cough or wheezing, possibly with white or pink mucus
- Abdominal bloating due to fluid buildup

This type of cardiomyopathy can lead to heart failure and other complications if not managed properly. Regular monitoring and appropriate treatment are crucial.
Prognosis: Prognosis: Dilated cardiomyopathy 1A (DCM1A) is a genetic form of dilated cardiomyopathy caused by mutations in the LMNA gene. The prognosis for individuals with DCM1A varies. Some may experience mild symptoms and maintain relatively normal heart function for many years, while others may progress to severe heart failure and complications such as arrhythmias or sudden cardiac death. Regular monitoring and medical management are essential for optimizing outcomes and improving the quality of life. Advanced treatments, including implantable devices or heart transplantation, may be necessary in severe cases.
Onset: Dilated cardiomyopathy 1A (DCM1A) typically has an onset in adulthood, but it can vary. Some individuals might develop symptoms as early as childhood or adolescence, while others may not exhibit any signs until later in life. The age of onset can be influenced by the specific genetic mutation and other individual factors.
Prevalence: Dilated cardiomyopathy (DCM) is a condition characterized by the dilation and impaired contraction of the left or both ventricles. The prevalence of all types of DCM is estimated to be around 1 in 250 individuals. However, specific data on the prevalence of dilated cardiomyopathy type 1A (DCM1A), a genetic form of the disease often linked to mutations in the LMNA gene, is not well-documented. This specific subtype may be less common, but precise prevalence rates are not available.
Epidemiology: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased because the heart's main pumping chamber is enlarged and weakened. For DCM type 1A, which is linked to mutations in the LMNA gene:

**Epidemiology:**
- DCM in general affects approximately 1 in 250 to 1 in 500 individuals.
- The prevalence of DCM caused by LMNA mutations is lower but significant given the variety of genetic factors involved. LMNA mutations account for about 5-8% of familial DCM cases.
- This form of DCM usually presents in middle age but can vary widely.
- Both males and females are affected, but there may be a higher penetrance in males.

**Nan:**
- NA (not applicable) since no specific "nan" (likely a typo or abbreviation not relevant to the disease) information pertains to DCM type 1A. If you meant a specific term, please clarify.

If you have any other questions or need further information, feel free to ask.
Intractability: Dilated cardiomyopathy (DCM) is generally considered a progressive and chronic condition, which makes it difficult to cure. Management focuses on controlling symptoms, slowing disease progression, and improving quality of life. Some cases of DCM may stabilize or improve with appropriate treatment, but the disease is often intractable, particularly in advanced stages.
Disease Severity: Dilated cardiomyopathy (DCM) is a condition where the heart's ability to pump blood is decreased because the heart's main pumping chamber, the left ventricle, is enlarged and weakened. The severity of dilated cardiomyopathy can vary widely among individuals. It ranges from mild impairment to severe heart failure. The progression and impact on the quality of life also vary depending on the underlying cause, response to treatment, and overall health of the individual.

Regarding "nan," no specific context is provided, but in data or computational terms, "nan" typically stands for "Not a Number" and indicates missing or undefined data. Therefore, if you're seeking specific numerical data or additional context for dilated cardiomyopathy type 1A and receive "nan," it means that information might be missing or not readily defined in the given dataset.
Healthcare Professionals: Disease Ontology ID - DOID:0110425
Pathophysiology: Dilated cardiomyopathy (DCM) is characterized by the dilation and impaired contraction of the left ventricle or both ventricles of the heart. The myocardium (heart muscle) becomes weakened and cannot pump blood efficiently, leading to heart failure and arrhythmias. The pathophysiology involves a variety of genetic and acquired factors. Genetic mutations, particularly in genes encoding cytoskeletal, sarcomeric, and nuclear envelope proteins, contribute significantly. Mutation in the LMNA gene, which encodes lamin A/C, is a notable cause of DCM1A. Non-genetic factors such as myocarditis, alcohol abuse, and exposure to certain toxins can also lead to DCM. The result is ventricular remodeling, decreased contractile function, and progressive heart failure.
Carrier Status: For dilated cardiomyopathy 1A, the carrier status typically refers to the presence of a gene mutation associated with the condition. In genetics, being a "carrier" means having one copy of a mutated gene that could potentially cause a disorder. However, dilated cardiomyopathy 1A can be inherited in various patterns, including autosomal dominant. In the case of autosomal dominant inheritance, having one mutated copy of the gene is enough to increase the risk of developing the condition, and carriers can often exhibit symptoms.

The term "nan" usually refers to "not a number" in computational contexts, and it doesn't have direct relevance to medical genetic terminology. If "nan" was intended to refer to something else, please provide further context.
Mechanism: Dilated cardiomyopathy type 1A (DCM1A) is a genetic disorder characterized by an enlarged and weakened heart muscle, which reduces the heart's ability to pump blood efficiently. The primary mechanism involves mutations in the **LMNA gene**, which encodes nuclear envelope proteins lamin A and lamin C.

**Molecular Mechanisms:**
1. **LMNA Mutations**: Mutations in the LMNA gene affect the structural integrity of the nuclear envelope, impacting cellular functions and leading to cardiac muscle weakness.
2. **Nuclear Envelope Defects**: Abnormal lamin proteins disrupt the mechanical stability and signaling pathways within the cardiac myocytes (heart muscle cells), contributing to cell damage and apoptosis (cell death).
3. **Impaired Mechanotransduction**: Lamin A/C plays a role in mechanotransduction, the process by which cells convert mechanical stimuli into biochemical signals. LMNA mutations can impair this process, exacerbating the heart’s response to stress and leading to pathological remodeling.
4. **Oxidative Stress and Inflammation**: These mutations may also increase susceptibility to oxidative stress and chronic inflammation, further damaging cardiac cells and contributing to the dilated phenotype.

Overall, the molecular defects involving LMNA lead to progressive heart muscle dilation, impaired contractility, and eventual heart failure.
Treatment: Treatment for dilated cardiomyopathy (DCM) type 1A generally includes the following approaches:

1. **Medications:**
- **ACE Inhibitors:** Help to relax blood vessels and make it easier for the heart to pump blood.
- **Beta-Blockers:** Reduce the heart's workload and help it beat more regularly.
- **Diuretics:** Help to reduce fluid build-up in the body.
- **Aldosterone Antagonists:** Help to remove excess sodium and reduce fluid retention.
- **Anticoagulants:** Reduce the risk of blood clots.

2. **Lifestyle Changes:**
- **Dietary Modifications:** Low-sodium diet to reduce fluid retention.
- **Exercise:** Regular, moderate exercise as advised by a physician.
- **Smoking Cessation and Alcohol Limitation:** Important for overall cardiovascular health.

3. **Medical Devices:**
- **Implantable Cardioverter-Defibrillators (ICDs):** Help to prevent sudden cardiac death by correcting life-threatening arrhythmias.
- **Cardiac Resynchronization Therapy (CRT):** A type of pacemaker therapy that improves the heart's efficiency.

4. **Surgical Options:**
- **Heart Transplant:** For severe cases where other treatments are ineffective.
- **Ventricular Assist Devices (VADs):** Mechanical pumps that support heart function temporarily or as a bridge to transplant.

5. **Regular Monitoring and Follow-Up:**
- Routine check-ups with a cardiologist to monitor the condition and adjust treatment as necessary.

Treatment plans are often tailored to the individual patient based on the severity of their condition and their overall health.
Compassionate Use Treatment: Dilated cardiomyopathy (DCM) 1A is a genetic form of dilated cardiomyopathy. For patients with advanced stages of this condition, and when conventional treatments are not effective, compassionate use treatments and off-label or experimental treatments may be considered.

**Compassionate use treatments:** These are experimental drugs or therapies made available to patients outside of clinical trials when no other options are available. The physician must apply for and receive approval from regulatory authorities and drug manufacturers to use these treatments.

**Off-label or experimental treatments:** Some examples include:
- **Mechanical assistance devices:** Left Ventricular Assist Devices (LVADs) can be used as a bridge to heart transplantation or as a long-term solution for patients with severe heart failure.
- **Gene therapy:** Though still in the experimental stage, gene therapy aims to correct the genetic mutations causing the disease.
- **Stem cell therapy:** Investigational use of stem cells to repair damaged heart tissue is ongoing but not yet standard.
- **Medications:** Certain pharmacological agents may be used off-label based on emerging evidence. For instance, beta-blockers, ACE inhibitors, or ARBs might be used even in the earlier stages to manage symptoms more aggressively.

These approaches are highly regulated and should be considered when discussing with a cardiologist specialized in genetic heart conditions and advanced heart failure management.
Lifestyle Recommendations: For patients with Dilated Cardiomyopathy 1A, lifestyle recommendations typically include:

1. **Regular Monitoring**: Regular check-ups with a cardiologist to monitor heart function and adjust treatments as needed.

2. **Medication Adherence**: Taking prescribed medications consistently to manage symptoms and prevent complications.

3. **Dietary Adjustments**: Following a heart-healthy diet, such as the DASH (Dietary Approaches to Stop Hypertension) diet, which emphasizes vegetables, fruits, whole grains, lean proteins, and reducing sodium intake.

4. **Exercise**: Engaging in moderate physical activity as recommended by a healthcare provider, avoiding overly strenuous activities that can stress the heart.

5. **Fluid Management**: Monitoring and potentially restricting fluid intake as advised by a healthcare provider to avoid fluid overload.

6. **Avoiding Alcohol and Tobacco**: Eliminating alcohol and tobacco use, as these can exacerbate heart problems.

7. **Weight Management**: Maintaining a healthy weight to reduce the strain on the heart.

8. **Stress Management**: Implementing stress-reduction techniques such as yoga, meditation, or therapy.

9. **Sleep**: Ensuring adequate and quality sleep to support overall health.

Patients should always consult their healthcare provider for personalized advice.
Medication: For dilated cardiomyopathy 1A, treatment typically focuses on managing symptoms and improving heart function. This can include:

1. **Angiotensin-Converting Enzyme (ACE) Inhibitors**: Such as enalapril or lisinopril to reduce blood pressure and decrease the heart's workload.
2. **Beta-Blockers**: Like carvedilol or metoprolol to improve heart function and reduce symptoms.
3. **Diuretics**: Such as furosemide to help reduce fluid retention.
4. **Aldosterone Antagonists**: Such as spironolactone to help control blood pressure and fluid retention.
5. **Digoxin**: To help improve heart strength and rhythm.

It's essential to work closely with a healthcare provider to determine the best treatment plan.
Repurposable Drugs: Research into repurposable drugs for dilated cardiomyopathy type 1A (DCM1A) is ongoing. Some drugs that have shown potential benefits, though not specifically approved for DCM1A, include:

1. **Beta-blockers** (e.g., Carvedilol, Metoprolol) - They help reduce the heart's workload and improve heart function.
2. **ACE inhibitors or ARBs** (e.g., Lisinopril, Losartan) - These drugs help relax blood vessels and improve blood flow.
3. **Aldosterone antagonists** (e.g., Spironolactone) - They help reduce fluid buildup and lessen the strain on the heart.
4. **ARNI** (Angiotensin receptor-neprilysin inhibitors, e.g., Sacubitril/Valsartan) - This combination helps reduce the heart strain and improve outcomes in heart failure.
5. **Ivabradine** - Specifically reduces heart rate, which can be beneficial in heart failure.
6. **SGLT2 inhibitors** (e.g., Dapagliflozin) - Initially for diabetes, these drugs have shown benefits in heart failure management.

It's important to consult with a healthcare professional for personalized treatment options.
Metabolites: Dilated Cardiomyopathy 1A (DCM1A) is primarily a genetic condition characterized by the dilation of the heart's left ventricle, leading to impaired cardiac function. Metabolic alterations associated with DCM1A can include changes in energy metabolism, lipid metabolism, and oxidative stress markers. However, there is no specific, widely recognized metabolite uniquely associated with DCM1A that stands out in the literature. It's important to collaborate with a healthcare provider for detailed metabolic profiling relevant to specific cases of DCM1A.
Nutraceuticals: For dilated cardiomyopathy 1A (DCM1A), there is limited evidence supporting the use of nutraceuticals specifically targeting this genetic form of the disease. However, some general nutraceutical interventions for dilated cardiomyopathy include:

1. **Coenzyme Q10 (CoQ10)**: May help improve heart muscle function.
2. **L-Carnitine**: Might enhance energy production in heart cells.
3. **Omega-3 Fatty Acids**: Can have anti-inflammatory effects and promote heart health.
4. **Taurine**: May support heart muscle function.

More research is needed to validate the efficacy of these nutraceuticals in DCM1A specifically. Always consult a healthcare provider before starting any new supplementation.

“NAN” likely refers to "not applicable or not available," indicating a lack of specific data or recommendations related to nutraceuticals for this condition.
Peptides: For dilated cardiomyopathy 1A (DCM1A), there aren't any specific peptides currently approved as standard treatment. However, ongoing research in the field of peptides and nanotechnology may explore future therapeutic avenues.